INTRODUCTION
============

Epidemiological studies have shown that the coffee consumption can reduce the incidence of human colorectal cancer ([@b9-bt-25-337]). A meta-analysis that combined the results of 12 case-control studies and five prospective cohort studies have shown that daily coffee consumption can lower a risk of human colorectal cancer by 24% compared to abstinence from it ([@b9-bt-25-337]).

Although many components of coffee beans have been reported to exert cancer chemoprotective effects ([@b4-bt-25-337]), kahweol as a diterpene molecule from coffee beans shows anti-cancer activity in human colorectal cancer ([@b8-bt-25-337]). Apart from human colorectal cancer, kahweol has anti-cancer properties against oral squamous cancer ([@b5-bt-25-337]), breast cancer ([@b3-bt-25-337]), pleural mesothelioma ([@b12-bt-25-337]), renal carcinoma ([@b20-bt-25-337]) and lung cancer ([@b11-bt-25-337]). In mechanistic studies for apoptotic effect of kahweol, it stimulated the cleavage of caspase-3 and poly ADP-ribose polymerase (PARP) by inhibiting the phosphorylation of a signal transducer and activator of transcription 3 (STAT3) in lung adenocarcinoma cells ([@b11-bt-25-337]). In addition, kahweol has been reported to sensitize TRAIL-induced apoptosis through down-regulation of Bcl-2 and c-FLIP in renal carcinoma cells ([@b20-bt-25-337]). In human colorectal cancer cells, kahweol mediated apoptosis by suppressing heat shock protein 70 expression ([@b8-bt-25-337]). Although some molecular targets for kahweol-mediated apoptosis have been elucidated, the further mechanism for apoptotic effect of kahweol is not known.

Activating transcription factor 3 (ATF3) as a member of the ATF/CREB subfamily of the basic-region leucine zipper (bZIP) family ([@b10-bt-25-337]) exhibits tumor suppressor function in the development of human colorectal cancer. ATF3 can enhance the activation of p53 ([@b22-bt-25-337]), suppress Ras-mediated tumorigenesis, and down-regulate cyclin D1 ([@b17-bt-25-337]) and MMP-2 expression ([@b6-bt-25-337]). A number of phytochemicals showing anti-cancer activity such as indole-3-carbinol ([@b14-bt-25-337]), conjugated linoleic acid ([@b15-bt-25-337]), epicatechin gallate ([@b1-bt-25-337]), and resveratrol ([@b21-bt-25-337]) have been reported to induce apoptosis by activating ATF3 expression. Furthermore, ATF3 is a target of some anticancer drugs such as cisplatin ([@b19-bt-25-337]) and bortezomib ([@b2-bt-25-337]).

In this report, we investigated the molecular mechanism of kahweol-mediated ATF3 expression and apoptosis in human colorectal cancer cells.

MATERIALS AND METHODS
=====================

Chemical reagents
-----------------

Kahweol was purchased from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco's Modified Eagle medium (DMEM)/F-12 1:1 Modified medium (DMEM/F-12) was purchased from Lonza (Walkersville, MD, USA). Antibodies against ATF3, Poly ADP ribose polymerase (PARP) and β-actin were purchased from Cell Signaling (Beverly, MA, USA). PD98059 (ERK1/2 inhibitor), SB203580 (p38 inhibitor), SP600125 (JNK inhibitor) and LiCl (GSK3β inhibitor) were purchased from Calbiochem (San Diego, CA, USA). ATF3 siRNA was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). ATF3 promoter constructs used in this study were kindly provided by Dr. Seong Ho Lee (University of Maryland, College Park, MD, USA). All chemicals were purchased from Fisher Scientific (Hampton, NH, USA), unless otherwise specified.

Cell culture and treatment
--------------------------

Human colorectal cancer cell lines (HCT116, SW480, LoVo and HT-29) were purchased from Korean Cell Line Bank (Seoul, Korea) and grown in DMEM/F-12 supplemented with 10% fatal bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin. The cells were maintained at 37°C under a humidified atmosphere of 5% CO~2~. Kahweol was dissolved in dimethyl sulfoxide (DMSO) and treated to cells. DMSO was used as a vehicle and the final DMSO concentration did not exceed 0.1% (v/v).

Reverse transcriptase-polymerase chain reaction (RT-PCR)
--------------------------------------------------------

After kahweol treatment, total RNA was prepared using a RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and 1 μg of total RNA was reverse-transcribed using a Verso cDNA Kit (Thermo Scientific, Pittsburgh, PA, USA) according to the manufacturer's protocol for cDNA synthesis. PCR was performed using PCR Master Mix Kit (Promega, Madison, WI, USA) with human primers for ATF3 and GAPDH as followed: human ATF3: 5′-GTTTGAGGATTTTGCTAACCTGAC-3′, and reverse 5′-AGCTGCAATCTTATTTCTTTCTCGT-3′; human GAPDH: forward 5′-ACCCAGAAGACTGTGGATGG-3′ and reverse 5′-TTCTAGACGGCAGGTCAGGT-3′.

Transient transfections
-----------------------

Transient transfections were performed using the PolyJet DNA transfection reagent (SignaGen Laboratories, Ijamsville, MD, USA) according to the manufacturers' instruction. Cells were plated in 12-well plates at a concentration of 2×10^5^ cells/well. After growth overnight, plasmid mixtures containing 1 μg of ATF3 promoter linked to luciferase and 0.1 μg of pRL-null vector were transfected for 24 h. The transfected cells were cultured in the absence or presence of kahweol. The cells were then harvested in 1×luciferase lysis buffer, and luciferase activity was normalized to the pRL-null luciferase activity using a dual-luciferase assay kit (Promega).

Transfection of small interference RNA (siRNA)
----------------------------------------------

HCT116 cells were plated in 6-well plates and incubated overnight. HCT116 cells were transfected with control siRNA and ATF3 siRNA for 48 h at a concentration of 100 nM using TransIT-TKO transfection reagent (Mirus, Madison, WI, USA) according to the manufacturer's instruction. Then the cells were treated with 50 μM of kahweol for 24 h.

Expression vector
-----------------

ATF3 expression vector was provided from Addgene (Cambridge, MA, USA). Transient transfection of the vector was performed using the PolyJet DNA transfection reagent (Signa-Gen Laboratories) according to the manufacturers' instruction.

SDS-PAGE and Western blot
-------------------------

After kahweol treatment, cells were washed with 1×phosphate-buffered saline (PBS), and lysed in radioimmunoprecipitation assay (RIPA) buffer (Boston Bio Products, Ashland, MA, USA) supplemented with protease inhibitor cocktail (Sigma-Aldrich) and phosphatase inhibitor cocktail (Sigma-Aldrich), and centrifuged at 15,000×g for 10 min at 4°C. After determining protein concentration by the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL, USA), the proteins were separated on SDS-PAGE and transferred to PVDF membrane (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The membranes were blocked for non-specific binding with 5% non-fat dry milk in Tris-buffered saline containing 0.05% Tween 20 (TBS-T) for 1 h at room temperature and then incubated with specific primary antibodies in 5% non-fat dry milk at 4°C overnight. After three washes with TBS-T, the blots were incubated with horse radish peroxidase (HRP)-conjugated immunoglobulin G (IgG) for 1 h at room temperature and chemiluminescence was detected with ECL Western blotting substrate (Amersham Biosciences, Piscataway, NJ, USA) and visualized in Polaroid film.

Statistical analysis
--------------------

All the data are shown as mean ± SEM (standard error of mean). Statistical analysis was performed with one-way ANOVA followed by Dunnett's test. Differences with ^\*^*p*\<0.05 were considered statistically significant.

RESULTS
=======

Kahweol mediates apoptosis in human colorectal cancer cells
-----------------------------------------------------------

To determine pro-apoptotic effect of kahweol in human colorectal cancer cells, HCT116 cell were treated with 0, 12.5, 25 and 50 μM of kahweol for 24 h. After kahweol treatment, Western blot was performed against the cleaved PARP. As shown in [Fig. 1A](#f1-bt-25-337){ref-type="fig"}, cleaved PARP was slightly increased in HCT116 cells treated with 25 μM of kahweol. However, treatment of kahweol at 50 μM significantly increased the cleaved PARP. In addition, 50 μM of kahweol induced the cleaved PARP in SW480, LoVo and HT-29 cells ([Fig. 1B](#f1-bt-25-337){ref-type="fig"}). These findings indicate that kahweol may induce apoptosis in human colorectal cancer cells.

ATF3 expression contributes to kahweol-mediated apoptosis
---------------------------------------------------------

To investigate whether kahweol affects ATF3 expression, the cells were treated with kahweol for 24 h and then Western blot was performed using ATF3 antibody. Kahweol dose-dependently increased ATF3 protein level in HCT116 cells ([Fig. 2A](#f2-bt-25-337){ref-type="fig"}). In addition, increased ATF3 protein level was observed in SW480, LoVo and HT-29 cells treated with kahweol ([Fig. 2B](#f2-bt-25-337){ref-type="fig"}). In time-course experiment, ATF3 protein level started increasing at 3 h after kahweol treatment ([Fig. 2C](#f2-bt-25-337){ref-type="fig"}). Next, we investigated the effect of ATF3 expression by kahweol on apoptosis using ATF3 expression construct and ATF3 siRNA. As shown in [Fig. 2D](#f2-bt-25-337){ref-type="fig"}, ATF3 overexpression increased PARP cleavage by kahweol. Furthermore, ATF3 knockdown by ATF3 siRNA attenuated kahweol-mediated cleavage of PARP ([Fig. 2E](#f2-bt-25-337){ref-type="fig"}). These findings indicate that kahweol-mediated ATF3 expression may contribute to apoptosis in human colorectal cancer cells.

Kahweol-mediated ATF3 expression results from transcriptional regulation
------------------------------------------------------------------------

To determine whether the upregulation of ATF3 protein by kahweol is induced by transcriptional regulation, mRNA level was tested using RT-PCR. As shown in [Fig. 3A](#f3-bt-25-337){ref-type="fig"}, kahweol upregulated mRNA level of ATF3 in HCT116, SW480, LoVo or HT-29 cells, which was similar to the effect of kahweol on ATF3 protein level. To confirm that kahweol activates ATF3 transcription, ATF3 promoter activity was measured and we observed that ATF3 promoter activity was also enhanced by kahweol treatment in HCT116, SW480, LoVo or HT-29 cells ([Fig. 3B](#f3-bt-25-337){ref-type="fig"}). In time-course experiment, ATF3 promoter activity started being activated at 3 h after kahweol treatment ([Fig. 3C](#f3-bt-25-337){ref-type="fig"}). These data indicate that kahweol-mediated ATF3 promoter activation may be responsible for the upregulation of ATF3 protein level in human colorectal cancer cells.

CREB is responsible for kahweol-induced ATF3 promoter activation
----------------------------------------------------------------

To determine a specific site of ATF3 promoter associated with kahweol-induced ATF3 promoter activation, ATF3 promoter luciferase constructs (pATF3-1420/+34, pATF3-718/+34, pATF3-514/+34, pATF3-318/+34, pATF3-147/+34 and pATF3-84/+34) were transfected into HCT116 cells and treated with 50 μM of kahweol for 24 h. As shown in [Fig. 4A](#f4-bt-25-337){ref-type="fig"}, the fold inductions were 7.0, 7.0, 6.9, 7.2, 7.2 and 3.2 in pATF3-1420/+34, pATF3-718/+34, pATF3-514/+34, pATF3-318/+34, pATF3-147/+34 and pATF3-84/+34, respectively. Kahweol increased ATF3 promoter activity by 7-fold using ATF3 promoter construct containing −147 to −84 region while kahweol slightly increased ATF3 promoter activity using a construct without −147 to −85 region, which suggests that kahweol-responsible elements may be between the −147 and −85 region in ATF3 promoter. The Fushi tarazu (Ftz) and CREB have been reported to be cis-acting elements in ATF3 promoter containing −147 and −85 ([@b7-bt-25-337]). To identify the role of each cis-acting element, each site-deleted ATF3 promoter constructs were transfected into HCT116 cells and treated with 50 μM of kahweol. As shown in [Fig. 4B](#f4-bt-25-337){ref-type="fig"}, kahweol-induced ATF3 promoter activity was significantly decreased when the CREB site was deleted. However, the deletion of Ftz sites did not affect ATF3 promoter activity by kahweol. These data indicate that CREB may be important for kahweol-induced ATF3 expression.

Kahweol-induced ATF3 expression is dependent on ERK1/2 and GSK3β
----------------------------------------------------------------

To elucidate the upstream kinases associated with ATF3 expression by kahweol, each kinase inhibitor such as PD98059 (ERK1/2 inhibitor), SB203580 (p38 inhibitor), SP600125 (JNK inhibitor) or LiCl (GSK3β inhibitor) was pretreated in HCT116 cells and then co-treated with kahweol. As shown in [Fig. 5](#f5-bt-25-337){ref-type="fig"}, inhibition of ERK1/2 by PD98059 or GSK3β by LiCl attenuated kahweol-mediated ATF3 expression ([Fig. 5A, 5D](#f5-bt-25-337){ref-type="fig"}). However, inhibition of other kinase did not affect ATF3 expression by kahweol ([Fig. 5B, 5C](#f5-bt-25-337){ref-type="fig"}). These data indicate that ERK1/2 and GSK3β may be major upstream kinases for kahweol-mediated ATF3 expression.

DISCUSSION
==========

Because many phytochemicals with anti-cancer activity act through the induction of apoptosis, induction of apoptosis has been regarded as an effective strategy in cancer chemoprevention and chemotherapy. Kahweol as a coffee-specific diterpene has been reported to induce apoptosis via downregulating STAT3 signaling pathway in human adenocarcinoma cells ([@b11-bt-25-337]). However, the other precise mechanisms of its apoptotic effect remain unclear. In the present study, we demonstrated that kahweol induces apoptosis via upregulation of ATF3 in human colorectal cancer cells. We showed that kahweol increases the cleavage level of PARP in HCT116, SW480, LoVo and HT-29 cells, indicating that human colorectal cancer cells treated with kahweol underwent apoptosis. In addition, we found that kahweol activates ATF3 expression and knockdown of ATF3 by siRNA or ATF3 overexpression by ATF3 expression vector decreases or increases kahweol-mediated cleavage of PARP, respectively. These findings suggest that ATF3 may be an important molecular target for kahweol-mediated apoptosis. Indeed, ATF3 has been reported to play an important role for the induction of apoptosis by many anti-cancer phytochemicals such as indole-3-carbinol, conjugated linoleic acid, epicatechin gallate and resveratrol ([@b1-bt-25-337]; [@b14-bt-25-337], [@b15-bt-25-337]; [@b21-bt-25-337]). However, it is the first report to identify ATF3 as a molecular target in apoptotic effect of kahweol.

Furthermore, we found that kahweol-mediated increase of ATF3 protein level is through transcriptional regulation and kahweol-responsible promoter region is between the −147 and −85 region. The ATF3 promoter contains a variety of response elements ([@b16-bt-25-337]). In ATF3 promoter containing −147 to −85, Fushi tarazu (Ftz) and CREB have been reported to be cis-acting elements ([@b7-bt-25-337]). Deletion of CREB binding site attenuated ATF3 promoter activity by kahweol compared to wild type or deletion of Ftz. There is growing evidence that kahweol induces the phosphorylation of CREB ([@b18-bt-25-337]). These findings suggest that CREB is an important cis-acting element associated with kahweol-mediated ATF3 activation. However, we did not exclude other cis-acting elements containing −84 to +34 because kahweol slightly increased ATF3 promoter activity in the cells transfected with ATF3 promoter construct containing −84 to +34.

There is growing evidence that ATF3 expression is regulated by various upstream kinases including MAPK suck as ERK1/2, p38 and JNK ([@b1-bt-25-337]; [@b13-bt-25-337]), and GSK3β ([@b15-bt-25-337]). In this study, we found that inhibition of ERK1/2 by PD98059 and GSK3β by LiCl attenuates kahweol-induced ATF3 expression, which ERK1/2 and GSK3β may be important kinases for activating ATF3 expression by kahweol. However, further study is required to explain the more detailed information on how ATF3 interact with ERK1/2 or GSK3β in response to kahweol.

The current data demonstrate that kahweol increases ERK1/2 or GSK3β-dependent ATF3 expression through transcriptional regulation, which might be associated with the induction of apoptosis in human colorectal cancer cells. In addition, the current study can provide the additional information for the molecular target of kahweol's anti-cancer activity although many molecular targets for the anti-cancer activity of kahweol have been elucidated.
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![The effect of kahweol on apoptosis in human colorectal cancer cells. (A) HCT116 cells were treated with 0, 12.5, 25 and 50 μM of kahweol for 24 h. (B) SW480, LoVo or HT-29 cells were treated with 50 μM of kahweol for 24 h. Cell lysates were subjected to SDS-PAGE and Western blot was performed using antibodies against cleaved PARP and actin. ^\*^*p*\<0.05 compared to cells without kahweol. All experiments were repeated three times.](bt-25-337f1){#f1-bt-25-337}

![The effect of kahweol on ATF3 expression and ATF3-mediated apoptosis in human colorectal cancer cells. HCT116 cells were treated with 0, 12.5, 25 and 50 μM of kahweol for 24 h. (B) SW480, LoVo or HT-29 cells were treated with 50 μM of kahweol for 24 h. (C) HCT116 cells were treated with 50 μM of kahweol for the indicated times. (D) HCT116 cells were transfected with ATF3 expression vector for 24 h and then co-treated with 50 μM of kahweol for the additional 24 h. (E) HCT116 cells were transfected with control- or ATF3 siRNA for 48 h and then co-treated with 50 μM of kahweol for the additional 24 h. Cell lysates were subjected to SDS-PAGE and Western blot was performed using antibodies against ATF3, cleaved PARP or actin. ^\*^*p*\<0.05 compared to cells without kahweol (A--C), control expression vector (D) or control siRNA (E). All experiments were repeated three times.](bt-25-337f2){#f2-bt-25-337}

![The effect of kahweol on ATF3 transcriptional activation. (A) HCT116, SW480, LoVo or HT-29 cells treated with kahweol for 24 h and then total RNA was isolated and RT-PCR was performed. (B) The pATF3-1420/+34 construct (1 μg) was co-transfected with pRL-null vector (0.1 μg) into HCT116, SW480, LoVo or HT-29 cells. The cells were treated with kahweol for 24 h and then luciferase activity was measured. (C) The pATF3-1420/+34 construct (1 μg) was co-transfected with pRL-null vector (0.1 μg) into HCT116 cells. The cells were treated with 50 μM of kahweol for the indicated times and then luciferase activity was measured. ^\*^*p*\<0.05 compared to cells without kahweol. All experiments were repeated three times.](bt-25-337f3){#f3-bt-25-337}

![Identification of ATF3 promoter sites responsible for kahweol-induced ATF3 transcriptional activation. (A, B) Each indicated construct of the ATF3 promoter (1 μg) was co-transfected with 0.1 μg of pRL-null vector into HCT116, and then cells were treated with 50 μM of kahweol. Luciferase activity was measured. ^\*^*p*\< 0.05 compared to cells transfected with luciferase construct containing −1420 to +34 of human ATF3 promoter region or pATF3-514 wild type. All experiments were repeated three times.](bt-25-337f4){#f4-bt-25-337}

![Dependency of ERK1/2 and GSK3β in kahweol-mediated ATF3 expression. HCT116 cells were pretreated with PD98059 (40 μM, ERK1/2 inhibitor) (A), SB203580 (40 μM, p38 inhibitor) (B), SP600125 (40 μM, JNK inhibitor) (C) or LiCl (20 mM, GSK3β inhibitor) (D) for 2 h and then co-treated with 50 μM of kahweol for 10 h. Cell lysates were subjected to SDS-PAGE and Western blot was performed using antibodies against ATF3 or actin. ^\*^*p*\<0.05 compared to cells with DMSO and kahweol. All experiments were repeated three times.](bt-25-337f5){#f5-bt-25-337}
